India shares higher at close of trade; Nifty 50 up 1.08%
Investing.com – India equities were higher at the close on Wednesday, as gains in the Metals, Banking and Auto sectors propelled shares higher. At the close in NSE, the Nifty 50 added...
Strong Buy
or
Sun Pharma News & Analysis
-
-
Morning Scan: Maruti Suzuki Flags Production Slump, NTPC’s Capacity to Rise & More
By Malvika Gurung Investing.com -- The Nifty 50 Futures listed on the Singapore-based Exchange SGX, an early indicator for Nifty50, was found trading 0.41% higher at 8:30 am on Wednesday,...
-
Sun Pharma arm settles trade secrets case for $22.5 mn
Sun Pharmaceutical Industries on Tuesday said its arm DUSA Pharmaceuticals Inc has reached settlement with Biofrontera to resolve a litigation over misappropriation of trade secrets and...
-
Sun Pharma arm settles case with Biofrontera, to get USD 22.5 mn
In 2018, DUSA Pharmaceuticals had filed a suit at the US District Court of Massachusetts against Biofrontera Inc Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG...
-
India shares higher at close of trade; Nifty 50 up 0.16%
Investing.com – India equities were higher at the close on Monday, as gains in the Technology, IT and Consumer Durables sectors propelled shares higher. At the close in NSE, the Nifty 50...
-
Markets trade higher despite weak global cues; Sensex nears 58,900, Nifty 50 over 17,560; Bharti Airtel, RIL, Sun Pharma, Power Grid shine
PSU Bank has outperformed, while oil & gas and telecom stocks also witnessed substantial gains. India's volatility index has nosedived nearly 11%.
-
Sensex falls 600 pts dragged by energy stocks; RIL, Bajaj Finance top losers
Indian share markets trade lower with the BSE Sensex down by 620 points, while the Nifty is down 177 points
-
Stocks in news: Reliance Industries, IRCTC, Sun Pharma, Bharti Airtel, Paytm and more
On Thursday, benchmark indices ended lower for the third straight session, tracking losses in index majors L&T, Infosys and TCS amid a negative trend in global markets.
-
Stocks in the news: Paytm, Latent View, Reliance Ind, Sun Pharma, IRB Infra and Laurus Labs
Zydus Cadila said it has received approval from the US health regulator to market Decitabine injection, used to treat certain types of cancers, in the American market.
-
Stocks to Watch: Maruti, Reliance, PNB, Sun Pharma, Paytm
The market is expected to react to the news of scrapping of contentious farm laws and the decision of Reliance Industries and Saudi Aramco to re-evaluate the proposed investment in the...
-
Sun Pharma recalls products in US market
The US arm of the domestic pharma major is recalling Tadalafil tablets in the American market, according to the latest enforcement report of the US Food and Drug Administration...
-
Sun Pharma recalls over 1.10 lakh bottles of generic drug in US market
New Delhi, Nov 21 Drug major Sun Pharmaceutical Industries is recalling over 1.10 lakh bottles of a generic medication used to treat erectile dysfunction in men in the US market due to a...
-
Sun Pharma, other drug cos say innovative products to contribute substantially in future
Sun Pharma, India's largest drug maker, said it expects its innovative products to garner $1.5 billion in sales in the next 3-4 years.
-
Markets gain momentum; Sensex regains 61k, Nifty 50 around 18,200; Bank, Consumer Durables outperform; ITC, Asian Paints, Sun Pharma top bulls
In the opening bell, Sensex has touched an intraday high of 61,036.56 and Nifty 50 rose to more than 18,210.
-
Stocks in Focus on Nov 12; Tata Steel, Coal India, Zee & More
By Malvika Gurung Investing.com -- Tata Steel (NS:TISC): The steelmaking company reported a rise in consolidated net profit of 661% YoY to Rs. 11,918.11 crore for the quarter ended...
-
Stocks in focus: Sun Pharma, IndiaBulls Housing Fin, Zee Ent, NLC India and more
Nifty futures on the Singapore Exchange traded 59.5 points, or 0.33 per cent higher at 17,986, signaling that Dalal Street was headed for a positive start on Friday. Here are a dozen stocks...
-
Sun Pharma to launch Merck's Covid pill under brand name 'Molxvir' in India
Sun Pharmaceutical Industries said it is gearing up to introduce Merck Sharp Dohme and Ridgeback's molnupiravir under the brand name Molxvir in India
-
Sun Pharma says gearing up to launch COVID drug molnupiravir
The company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COVID-19 in adults. Earlier this year, Sun Pharma had...
-
Sun Pharma to introduce oral antiviral for treatment of Covid-19 in India
Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID -19 in adults. It is under...
-
Nifty Pharma sheds 1.5% with majority stocks in free fall; Natco dives 6% ahead of Q2; Laurus Labs, Strides, Aurobindo, Sun Pharma drag too
Except for Torrent Pharma and IPCA Lab, all other stocks listed on the Nifty Pharma are trading in the red.
-
Lupin, Sun Pharma confirms voluntary recall of products in US market; Stocks trade mixed
Both the companies have clarified stock exchanges over news reports claiming the same.
-
Sun Pharma might finally have a prescription for the specialty dream
The ramp-up in its specialty business over the past year has increasingly turned skeptics into believers. The company has four major products in the trial phase, which suggests that the...
-
Sun Pharma's two US subsidiaries to pay $85M in settlement pacts over antritrust litigation
The settlement payment amounts will be reduced by US$10 Million if the direct purchasers that opt out of the putative class collectively account for 20 percent or more of Taros and SPIIs...
-
-
Grasim Industries, Sun Pharma, PVR, Lupin in focus
Grasim Industries said it commissioned Chloromethane (CMS) project at Vilayat Unit in Gujarat on 4 November 2021. Grasim Industries said the project has a capacity of 150 ton per day (TPD) /...
-
Stocks in the news: TaMo, SBI, Sun Pharma, GAIL, NMDC and IOC
Britannia Industries, Sobha, Aurobindo Pharma, Shyam Metalics and Energy, EID Parry (India), V-Mart Retail, 3i Infotech, Balrampur Chini Mills, KRBL, Elgi Equipments, Vijaya Diagnostics...
-
Sun Pharma rating – Add: Performance in second quarter was strong
Ramp-up in specialty biz bodes well; FY22-24e EPS up 6%; TP revised to Rs 915; ‘Add’ rating maintained
-
Leading drug makers Sun Pharma, Lupin recall products in US market
According to USFDA, the Mumbai-based drug maker is recalling the affected lot due to "failed moisture limits."
-
Sun Pharma, Lupin recall products in US market, says USFDA
As per the latest enforcement report by the US Food and Drug Administration (USFDA), Sun Pharma is recalling 22,752 blister packs of Loratadine-D extended-release tablets, used for the...
-
Sun Pharma, Lupin start recalling products from US market
According to USFDA, the Mumbai-based drug maker is recalling the affected lot due to "failed moisture limits."
-
Sun Pharma, Lupin recall products in US market
According to USFDA, the Mumbai-based drug maker is recalling the affected lot due to "failed moisture limits."
-
Sun Pharma's two US arms to pay $85 million
The subsidiaries will make an aggregate payment amounting to a combined total of $85 million in exchange for a full release of all claims asserted against them in the direct purchaser action...
-
Sun Pharma's 2 US arms to pay USD 85 mn in settlement pacts over antritrust litigation
Under the terms of the settlement agreements, the subsidiaries will make an aggregate payment amounting to a combined total of USD 85 million in exchange for a full release of all claims...
-
Sun Pharma's two US arms to pay $85 mn in settlement pacts over antritrust litigation
Sun Pharma units have signed settlement agreements with the Direct Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing Antitrust Litigation
-
Buy Sun Pharmaceutical Industries; target of Rs 965: ICICI Direct
ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 965 in its research report dated November 03, 2021.
-
Most analysts raise target prices on Sun Pharma after strong Q2
CLSA, which raised the target price on Sun Pharma the most, said the drug maker's results were above estimates with key geographies performing well. Sun Pharma shares ended down 3.3% at ₹788...
-
India shares lower at close of trade; Nifty 50 down 0.33%
Investing.com – India equities were lower at the close on Wednesday, as losses in the Banking, Auto and Consumer Durables sectors propelled shares lower. At the close in NSE, the Nifty 50...
-
Hold Sun Pharma; target of Rs 775: Emkay Global Financial
Emkay Global Financial recommended hold rating on Sun Pharma with a target price of Rs 775 in its research report dated November 03, 2021.
-
2 Pharma Stocks To Buy From ICICI Securities
ICICI Securities has recommended 2 pharma stocks to buy, namely Ajanta Pharma and Sun Pharmaceutical Industries (SUNPHA). These 2 pharma companies have exhibited considerable growth in past...
-
Buy Sun Pharma; target of Rs 970: Motilal Oswal
Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 970 in its research report dated Novemer 03, 2021.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
